Salary, Integrity and Selection of a New Chair for California’s $12 Billion Cell and Gene Therapy Enterprise
By David Jensen,
The California Stem Cell Report
| 05. 20. 2022
Photo by Giorgio Trovato on Unsplash
The directors of the $12 billion California stem cell agency are looking for a new chair who is both decisive and collaborative, passionate and inclusive. But at the top of the wish list is a person who is a pillar of integrity.
At least that is what a survey of the 35 board members showed today. The results were released this afternoon, less than one business day before the directors’ Governance Subcommittee takes up the matter of compensation and qualifications for the new chair.
The post carries a salary range that currently tops out at $566,500 annually. But that could be boosted by the directors of the California Institute for Regenerative Medicine (CIRM), as the agency is officially known. Also figuring into the salary is whether the post should be a full-time job.
The new chair will oversee CIRM during the next decade or so, a period in which its results are likely to determine whether it lives or dies. Depending on its pace of spending, the agency will run out of cash...
Related Articles
By Dr. Coco Newton, Progress Educational Trust | 03.30.2026
Have you ever wondered what it means to have dozens of half-siblings across the world – or to never know where half of your genetic identity comes from? A recent episode of Zembla explores the human consequences of the global...
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...